The Different Design of Orthokeratology

Sponsor
Tianjin Eye Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT05956704
Collaborator
(none)
90
1
3
30
3

Study Details

Study Description

Brief Summary

In this study, we intend to enroll orthokeratology subjects aged 8-18 years old with binocular myopia up to and including -4.00 D. They were randomly selected to wear both orthokeratology of different designs, one with an aspheric wide inversion zone design in the optical zone and the other with a traditional spherical curved segment design, and to investigate the differences between these two lenses in terms of their effectiveness in myopia retardation, defocus, and aberration.

Condition or Disease Intervention/Treatment Phase
  • Device: Orthokeratology with aspheric wide inversion zone design in the optical zone
  • Device: Orthokeratology with traditional spherical design in the optical zone
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
90 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Care Provider, Investigator)
Primary Purpose:
Treatment
Official Title:
The Effectiveness and Safety of Different Design of Orthokeratology Lenses to Reduce Myopia Growth
Actual Study Start Date :
Dec 1, 2020
Actual Primary Completion Date :
Jun 1, 2023
Actual Study Completion Date :
Jun 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Experimental Group

Device: Orthokeratology with aspheric wide inversion zone design in the optical zone
An orthokeratology lens with an altered optical zone design is designed for an aspherical wide inversion arc in the optical zone

Active Comparator: Control group

Device: Orthokeratology with traditional spherical design in the optical zone
Subjects wore the orthokeratology with traditional spherical design in the optical zone

No Intervention: Blank control group

Outcome Measures

Primary Outcome Measures

  1. Changes in axial length [The change of baseline and 1years]

    Axial length was measured with a biometer

Eligibility Criteria

Criteria

Ages Eligible for Study:
8 Years to 18 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • The age is greater than 8 years and less than 18 years

  • The myopia was within -4.00D (including -4.00D), and the astigmatism was within 1.50D (including 1.50D) in both eyes.

  • Be able to complete 12 months of follow-up

  • They were able to understand the purpose of the trial, volunteered to participate, and signed informed consent by the subjects themselves or their legal guardians

Exclusion Criteria:
  • One eye met the inclusion criteria

  • Patients with systemic diseases causing immunocompromised or affecting orthokeratology

  • There are other eye diseases that affect orthokeratology lens wearing, such as dacryocystitis, blepharitis, various inflammation, glaucoma, etc

  • Abnormal cornea

  • Previous corneal surgery or corneal trauma history

  • Active keratitis (e.g., corneal infection)

  • Patients with best corrected distance visual acuity of less than 5.0

  • Patients with corneal flat curvature lower than 39.00D, or higher than 48.00D

  • Patients with refractive instability

  • Patients with overt strabismus

  • The corneal epithelium showed obvious fluorescent staining, which was not suitable for patients wearing orthokeratology lenses

  • Patients with dry eye are not suitable for orthokeratology

  • Patients with corneal endothelial cell density less than 2000 cells /mm2

  • Patients who had worn rigid contact lenses (including orthokeratology lenses) within the previous 30 days

Contacts and Locations

Locations

Site City State Country Postal Code
1 Tianjin Eye Hospital Tianjin China 300020

Sponsors and Collaborators

  • Tianjin Eye Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Tianjin Eye Hospital
ClinicalTrials.gov Identifier:
NCT05956704
Other Study ID Numbers:
  • KY2023031
First Posted:
Jul 21, 2023
Last Update Posted:
Jul 21, 2023
Last Verified:
Jul 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 21, 2023